Lead Discovery via Scaffold Refinement: Structure‐Guided Optimization of 1,2,4‐Triazolo[1,5‐ a ]Pyrimidines as Potent Dual EGFR/CDK‐2 Inhibitors Targeting Colorectal Carcinoma
Drug Development Research · 2026
DOI: 10.1002/ddr.70323 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Rowida Nasr und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. Hauptthemen laut MEDLINE: ErbB Receptors, Pyrimidines, Colorectal Neoplasms, Cyclin-Dependent Kinase 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben.
Abstract (Originalsprache)
A unique series of 1,2,4‐triazolo[1,5‐ a ]pyrimidine derivatives was designed and synthesized as potential dual inhibitors of EGFR and CDK‐2 to circumvent drug resistance in colorectal cancer patients through multi‐targeted therapy. When tested against HCT‐116 colorectal carcinoma cells, these compounds showed anticancer activity with lower toxicity against normal cells, thus providing a high selectivity index (> 2). Leads 12c , 12i , and 22 demonstrated potent kinase inhibition, with 22 yielding a CDK‐2 IC₅₀ of 0.03 µM (seliciclib: 0.02 µM), and 12c delivering an EGFR IC₅₀ of 0.12 µM (erlotinib: 0.01 µM). These leads induced G 2 /M cell cycle arrest and apoptosis in HCT‐116 cells via upregulation of Bax, cytochrome c, and caspase‐3, and downregulation of VEGF, AKT‐1, and Bcl‐2. Network pharmacology suggested EGFR and CDK‐2 as key targets. Redocking reference ligands erlotinib (EGFR, PDB: 1M17) and seliciclib (CDK‐2, PDB: 2A4L) confirmed docking poses, and binding interactions of 12c and 22 matched those of references. Using 100‐ns molecular dynamics simulations proved the stability of ligand‐protein complexes and further supported the reliability of predicted binding modes. Promising ADMET profiles and good drug likeness are evident in these leads. These data underscore the great potential of this scaffold for developing dual EGF/CDK‐2 inhibitors aimed at resistance mechanisms in more aggressive cancers and can thus be pursued further in preclinical optimization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
- Biochemistry and Molecular Biology Department, Faculty of Pharmacy, Capital University (formerly Helwan University), Cairo, Egypt.
- Helwan Structural Biology Center for Excellence, Capital University (formerly Helwan University), Cairo, Egypt.
- Department of Chemistry, College of Sciences, University of Sharjah, Sharjah, United Arab Emirates.
- Chemistry Department, Faculty of Science, Suez Canal University, Ismailia, Egypt.
ORCID-Profile: Hesham Haffez, Mohamed S Nafie, Ahmed R Ali
Zitieren
APA
Nasr, R., Haffez, H., Nafie, M. S., Moustafa, M. A. A., El-Kerdawy, M. M., & Ali, A. R. (2026). Lead Discovery via Scaffold Refinement: Structure‐Guided Optimization of 1,2,4‐Triazolo[1,5‐ a ]Pyrimidines as Potent Dual EGFR/CDK‐2 Inhibitors Targeting Colorectal Carcinoma. Drug Development Research. https://doi.org/10.1002/ddr.70323
Vancouver
Nasr R, Haffez H, Nafie MS, Moustafa MAA, El-Kerdawy MM, Ali AR. Lead Discovery via Scaffold Refinement: Structure‐Guided Optimization of 1,2,4‐Triazolo[1,5‐ a ]Pyrimidines as Potent Dual EGFR/CDK‐2 Inhibitors Targeting Colorectal Carcinoma. Drug Development Research. 2026. doi:10.1002/ddr.70323
BibTeX
@article{Nasr2026,
author = {Nasr, Rowida and Haffez, Hesham and Nafie, Mohamed S and Moustafa, Mohamed Ahmed A and El-Kerdawy, Mohamed M and Ali, Ahmed R},
title = {Lead Discovery via Scaffold Refinement: Structure‐Guided Optimization of 1,2,4‐Triazolo[1,5‐ a ]Pyrimidines as Potent Dual EGFR/CDK‐2 Inhibitors Targeting Colorectal Carcinoma},
journal = {Drug Development Research},
year = {2026},
doi = {10.1002/ddr.70323}
}
EUVIMED